Business Wire: October 26, 2016 – AUSTIN, TX, U.S.A. – Mati Therapeutics, Inc. (“Mati”) announced that it has been granted U.S. patent number 9,445,944 titled “Lacrimal Implants and Related Methods.” The patent, which expires in 2028, claims a method of providing a sustained drug release to an eye…
